Kymera Therapeutics’s Gollob sells $186k in shares
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics Inc stock price live, this page displays NASDAQ KYMR stock exchange data. View the KYMR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Kymera Therapeutics Inc real time stock price chart below.
What Is the Kymera Therapeutics Inc Stock Price Today?
The Kymera Therapeutics Inc stock price today is 58.26.
What Is the Stock Symbol for Kymera Therapeutics Inc?
The stock symbol for Kymera Therapeutics Inc is ""KYMR.""
What Stock Exchange Does Kymera Therapeutics Inc Trade On?
Kymera Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Kymera Therapeutics Inc a Good Stock to Buy?
Determining whether Kymera Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KYMR quote. (ISIN: US5015751044)
What Is the Kymera Therapeutics Inc Stock Price Today?
The Kymera Therapeutics Inc stock price today is 58.26.
What Is the Stock Symbol for Kymera Therapeutics Inc?
The stock symbol for Kymera Therapeutics Inc is ""KYMR.""
What Stock Exchange Does Kymera Therapeutics Inc Trade On?
Kymera Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Kymera Therapeutics Inc a Good Stock to Buy?
Determining whether Kymera Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KYMR quote. (ISIN: US5015751044)
NASDAQ
Currency in USD
Fair Value
An estimate of a Kymera's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
58.06
60.00
52 wk Range
19.45
60.00
Trading near 52-week High
1/3
Fair Value
An estimate of a Kymera's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
58.0660.00
52 wk Range
19.4560.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral
KYMR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Kymera's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
64.33
Upside
+10.42%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
11 analysts have revised their earnings upwards for the upcoming period
Kymera Therapeutics Inc Company Profile
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics Inc Earnings Call Summary for Q2/2025
- Q2 2025 EPS of -$0.95 missed forecast of -$0.83; revenue of $11.5M fell short of $20M expectation, causing 5.8% stock drop
- R&D expenses totaled $78.4M; cash position strong at $1B in July, extending runway into 2028
- Phase 1b data for KT621 program expected in Q4 2025; preparing for Phase 2b trials in atopic dermatitis and asthma
- Company aims to advance one new immunology program annually, focusing on oral degrader medicines for immune inflammatory diseases
- Revenue derived entirely from Sanofi collaboration; analysts concerned about dose selection strategy and IRAK4 candidate switch
Last Updated: 11/08/2025, 14:42
Read Full TranscriptCompare KYMR to Peers and Sector
Metrics to compare | KYMR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKYMRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −15.1x | −3.3x | −0.7x | |
PEG Ratio | 0.36 | 0.09 | 0.00 | |
Price/Book | 4.3x | 2.5x | 2.6x | |
Price / LTM Sales | 93.2x | 27.7x | 3.3x | |
Upside (Analyst Target) | 5.2% | 209.7% | 39.6% | |
Fair Value Upside | Unlock | 10.7% | 6.0% | Unlock |
Analyst Ratings
22 Buy
0 Hold
0 Sell
Ratings:
22 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 64.33
(+10.42% Upside)
Earnings
Latest Release
Aug 11, 2025
EPS / Forecast
-0.95 / -0.83
Revenue / Forecast
11.48M / 20.00M
People Also Watch
FAQ
What Stock Exchange Does Kymera Trade On?
Kymera is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Kymera?
The stock symbol for Kymera is "KYMR."
What Is the Kymera Market Cap?
As of today, Kymera market cap is 4.17B.
What Is Kymera's Earnings Per Share (TTM)?
The Kymera EPS (TTM) is -3.48.
When Is the Next Kymera Earnings Date?
Kymera will release its next earnings report on 29 Oct 2025.
From a Technical Analysis Perspective, Is KYMR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Kymera Stock Split?
Kymera has split 0 times.
How Many Employees Does Kymera Have?
Kymera has 218 employees.
What is the current trading status of Kymera (KYMR)?
As of 15 Oct 2025, Kymera (KYMR) is trading at a price of 58.26, with a previous close of 59.89. The stock has fluctuated within a day range of 58.06 to 60.00, while its 52-week range spans from 19.45 to 60.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.